Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 5/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24363770 | 0.90 | USP2 (0.49) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL13697423 | 0.89 | CYP3A4 (0.34) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL16116511 | 0.88 | GRIN2D (0.39) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL17281974 | 0.86 | GRIN2D (0.34) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL17281962 | 0.86 | USP2 (0.33) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL13050809 | 0.86 | GRIN2D (0.41) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL16117660 | 0.83 | GRIN2D (0.42) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL17281976 | 0.82 | GRIN2D (0.34) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL1753491 | 0.80 | USP2 (0.44) | OPRM1USP2CYP1A2TSHRCYP3A4 | |
| SCHEMBL4547459 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-11779586-B2 | Compounds comprising tricyclic heterocyclic compounds | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2023-10-10 | — | — | US | disclosed |
| US-11779586-B2 | Compounds comprising tricyclic heterocyclic compounds | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2023-10-10 | — | — | US | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9604984-B2 | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604984-B2 | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160347771-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2016-12-01 | — | — | US | disclosed |
| US-20160237043-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160237086-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-9346815-B2 | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150336962-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-11-26 | — | — | US | disclosed |
| US-8399465-B2 | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | OPRM1 1313/4885GRIN2D 2460/4885GRIN3B 1532/4885 |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | OPRM1 1863/4885GRIN2D 3102/4885GRIN3B 904/4885 |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | OPRM1 4620/4885GRIN2D 829/4885GRIN3B 2288/4885 |
| US-20150336962-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | OPRM1 3179/4885GRIN2D 1348/4885GRIN3B 2402/4885 |
| US-20160237043-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | OPRM1 4337/4885GRIN2D 4053/4885GRIN3B 2938/4885 |
| US-20160237086-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | OPRM1 3179/4885GRIN2D 1348/4885GRIN3B 2402/4885 |
| US-20160347771-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3CA, PIK3C2A, PIK3C2B | OPRM1 1538/4885GRIN2D 3553/4885GRIN3B 3620/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | OPRM1 4337/4885GRIN2D 4053/4885GRIN3B 2938/4885 |
| US-11779586-B2 | Compounds comprising tricyclic heterocyclic compounds | GRN, GLA, HTT | OPRM1 4084/4885GRIN2D 1568/4885GRIN3B 3115/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | OPRM1 4469/4885GRIN2D 999/4885GRIN3B 1856/4885 |
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | OPRM1 3179/4885GRIN2D 1348/4885GRIN3B 2402/4885 |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | OPRM1 2992/4885GRIN2D 1158/4885GRIN3B 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.